An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
- Registration Number
- NCT02258854
- Lead Sponsor
- XOMA (US) LLC
- Brief Summary
The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 69
Inclusion Criteria
- Completed either the X052130/CL3-78989-005 or the X052131/CL3-78989-006 study's masked D392 or OL-224 completion day visits or had controlled ocular inflammation after having received study drug in Part 2 of study X052133
Exclusion Criteria
- Discontinued from the previous study
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Dose 2 gevokizumab Dose 2 gevokizumab -
- Primary Outcome Measures
Name Time Method Treatment-emergent Adverse Events 108 weeks
- Secondary Outcome Measures
Name Time Method